We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PerkinElmer Introduces New Multispecies In Vivo Imaging Solution for Drug Development at AACR Annual Meeting
Product News

PerkinElmer Introduces New Multispecies In Vivo Imaging Solution for Drug Development at AACR Annual Meeting

PerkinElmer Introduces New Multispecies In Vivo Imaging Solution for Drug Development at AACR Annual Meeting
Product News

PerkinElmer Introduces New Multispecies In Vivo Imaging Solution for Drug Development at AACR Annual Meeting


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PerkinElmer Introduces New Multispecies In Vivo Imaging Solution for Drug Development at AACR Annual Meeting"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PerkinElmer, Inc., has announced a new Multispecies Imaging Module (MSIM) for PerkinElmer’s Fluorescence Molecular Tomography In Vivo Imaging Systems (FMT® 1500 or FMT® 2500LX). The new module enables researchers to generate 3D datasets of animal models relevant to disease research, including imaging capability for larger animals.

The multispecies imaging module allows researchers for the first time to deploy non-invasive fluorescence optical tomography (FMT) to generate quantitative 3D datasets from both small and large animal models.

Imaging larger animals has taken on greater importance since many disease models have been specifically developed based on rats, hamsters and guinea pigs, in addition to small animals such as mice. These disease states include oncology models and transplantation pathologies, autoimmune disorders, rheumatoid arthritis models, cardiovascular diseases, as well as metabolic diseases.

The 3D quantitative image datasets generated by the MSIM can be used for biodistribution, disease progresson and therapeutic response studies early in drug development pipelines. This enables researchers to filter out drug candidates that might otherwise have failed very expensively later in the drug development process.

“PerkinElmer is delighted to offer preclinical researchers expanded imaging and dataset-building capabilities for understanding disease,” said Achim von Leoprechting, vice president and general manager, Imaging and Detection Technologies, Bio-discovery, PerkinElmer, Inc.

Leoprechting continued, “Our new imaging module provides researchers working with large animal models with greater data quality and visibility. This technology gives them the same data building capability that they currently have with the conventional baseline of mice imaging - for animals up to 20 times larger than mice - for more disease-relevant data.”

The new MSIM docking station holds either the larger species cassette or an adapter that holds the original mouse cassette, allowing for sequential scans of rats, hamsters, guinea pigs and mice interchangeably. The proprietary fluorescence agent portfolio works equally well in the different animal models.

In addition, PerkinElmer’s TrueQuant™ analysis software has been upgraded for the new MSIM enabling fast reconstruction for the large image data files collected during a larger species scan.

Advertisement